Computational biology

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Computational biology, Malignancy, Canadian Aviation Regulations, Gene editing, Bone disease, Cell, Hook effect, CXCR4, Enfortumab vedotin, Synthetic biology, Patient, Neoplasm, Epitope, Differentiable function, Ink, PBMC, Protein engineering, HLA, Science, Cytotoxicity, AACR, Phenotype, Therapy, IPSC, Skin, Inflammation, Prognosis, Carcinogenesis, Rejection, CD22, VHH, Poster, NK, Century, Autoimmunity, Bone marrow, Engineering, CD19, Vaccine

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

Key Points: 
  • PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
  • This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
  • These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
  • In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, March 21, 2024
Research, Computational biology, AstraZeneca, Drug discovery, Half-life, Partnership, Executive, Patient, Conditional sentence, Biopharmaceutical, Insurance, Medicine, Dermatology, Investment, Therapy, Cryptocurrency

VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • "In 2023, Absci further solidified its leadership in AI-driven biologic drug discovery," said Sean McClain, Founder and CEO.
  • In January, Absci presented positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody, which exhibited properties consistent with a potentially superior product profile.
  • Based on further confirmatory studies, Absci selected a development candidate and initiated IND-enabling studies for ABS-101 in February 2024.
  • Cash, cash equivalents, and short-term investments as of December 31, 2023 were $97.7 million, compared to $113.5 million as of September 30, 2023.

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, March 14, 2024
EGFR, Gene editing, Cell, Immunotherapy, Patient, BMS, SLE, Bristol Myers Squibb, Protein engineering, IND, Investment, Therapy, CRS, Lymphoma, Research, Computational biology, ASH, Pharming, Investigational New Drug, IPSC, Cancer, Safety, Inflammation, Food, Cetuximab, AACR, Research and development, GAAP, NK, FDA, Administration, Ink, MBA, Abstract, Society, Rejection, Century, Autoimmunity, Pharmaceutical industry

PHILADELPHIA, March 14, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today reported financial results and business highlights for the full year ended December 31, 2023.

Key Points: 
  • In December 2023, Century presented initial clinical data from the Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory (r/r) B-cell lymphomas.
  • Data showed that CNTY-101 was well-tolerated at Dose Level 1 (100 million cells) in high-risk, heavily pretreated R/R B-cell lymphoma patients.
  • Net Loss: Net loss was $136.7 million for the year ended December 31, 2023, compared to $131.0 million for the year ended December 31, 2022.
  • The Company expects full year generally accepted accounting principles (GAAP) operating expenses to be between $135 million and $145 million.

MiLaboratories Introduces Platforma Bio: A Revolutionary UI-First Computational Biology Platform powered by AI

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Stem Cells, Software, Biotechnology, Health, Other Science, Science, Artificial Intelligence, Computational biology, Multimedia, NGS, Organization, Interest, UI, AI, Data analysis, Online shopping

MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio .

Key Points: 
  • MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio .
  • This groundbreaking computational biology platform, powered by AI large language models, is designed to significantly streamline, and simplify biological analysis, making it more accessible to researchers across various disciplines.
  • Platforma.bio stands out in the computational biology field with its unique, patent-pending engine that effectively identifies and eliminates redundant computations.
  • To introduce Platforma.bio to the research community, MiLaboratories will host a detailed webinar showcasing its features and practical applications.

Foundry Raises $80 Million in Seed and Series A Funding to Build a New Breed of Public Cloud

Retrieved on: 
Thursday, March 21, 2024
Internet, Data Management, Technology, Artificial Intelligence, Software, Deep learning, Computational biology, GPU, LG, Speed of light, MIT, Databricks, Pear VC, AI, Stanford University, Conviction, Civilization, M12 (venture capital), Lightspeed Venture Partners, Ecosystem, NEA, KKR, Economics, Sequoia Capital

Today, Foundry , a new breed of public cloud for AI/ML workloads, announced $80M in seed and Series A funding to orchestrate the world’s compute capacity, rendering it universally accessible and useful.

Key Points: 
  • Today, Foundry , a new breed of public cloud for AI/ML workloads, announced $80M in seed and Series A funding to orchestrate the world’s compute capacity, rendering it universally accessible and useful.
  • Foundry is building to ensure humanity maximizes the utility of the computing power we already have, and will produce.
  • Foundry’s innovative methods are solving these issues by providing scalable GPU instances with unmatched price-performance ratios.
  • If you are interested in becoming a customer or partner, or joining the team, please visit the company’s website .

City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Cancer

Retrieved on: 
Tuesday, March 12, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Hospitals, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Breast cancer, Syngenic, Convergent, Computational biology, Patient, Distinguishing, Beckman Research Institute, City, Tumor microenvironment, PSCA, Haematopoietic system, Memory, AACR, Lymphocyte, Treatment, Convergent Science, Neoplasm, Road, Systems biology, CRC, Division, Microbiome, Hematology, Pharmaceutical industry

To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

Key Points: 
  • To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.
  • They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.
  • , will also chair the inaugural AACR event called From Cancer Discoveries to Patients on April 4 and 5.
  • The event brings together leaders in clinical research, biotech and the investment community as part of AACR’s commitment to expediting the advancement of lifesaving cancer discoveries.

Biswas Family Foundation, Milken Institute Announce $15 Million in Funding for Research at the Intersection of AI and Health

Retrieved on: 
Tuesday, March 12, 2024
Technology, General Health, Infectious Diseases, Foundation, Philanthropy, Science, Biotechnology, Health, Health Technology, Other Philanthropy, Other Science, Research, Other Technology, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Gladstone Institutes, Diagnosis, Health informatics, Harvard Medical School, Computational biology, SPARC, Transformative use, Test management, Computer science, Data science, Disease, Assistant, Massachusetts Institute of Technology, Associate, Chatbot, Partnership, Genetics, Patient, Common, Artificial intelligence, AI, Doctor of Philosophy, Interpretation, Investment, Stanford University, Milken Institute, Genetic distance, Medical device

The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .

Key Points: 
  • The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .
  • Five multidisciplinary research teams will receive nearly $14 million total in grant funding for projects aiming to drive translational impact and the advancement of artificial intelligence (AI) models in clinical settings for diagnosis and treatment.
  • Additional support to enhance AI and computational biology research, inclusive of a gift to the Arc Institute , marks a total of $15 million in giving for the Biswas Family Foundation for this interdisciplinary field, and the beginning of more support.
  • To learn more about the Transformative Computational Biology Grant Program and to read the Giving Smarter Guide, visit: https://bit.ly/3Vae8Kq .

Pelvital Announces Advisory Board, Fueling its Mission to Transform the Standard of Care for Urinary Incontinence

Retrieved on: 
Tuesday, April 2, 2024
University, Obstructive sleep apnea, Patient, Pelvic pain, Vocational education, Urodynamic testing, Engineering, Gender, Champaign–Urbana metropolitan area, Pelvic organ prolapse, Carlson School of Management, UnitedHealth Group, Incontinence, Woman, Safety, Strategic communication, Organization, Biomedical engineering, Advisory board, Neurology, Female, Sport, Associate, Research, MD, UIT, Tetraplegia, Urinary incontinence, Biology, Book, FDA, Medtech, Health, Visibility, Growth, Computational biology, Arizent, Mechanical engineering, Physiology, M Health Fairview, Doctor of Philosophy, Integrative Biology, Faculty, Urogynecology, Human, MBA, News, Government, Rehabilitation, Nursing

EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board. This dynamic team of industry leaders and experts will play a pivotal role in supporting the strategic direction and growth of the organization in its ongoing efforts to expand its reach with clinicians, patients, and payors seeking an effective, accessible, conservative treatment option.

Key Points: 
  • EAGAN, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- Pelvital, the women's health MedTech company on a mission to transform the standard of care for urinary incontinence, is proud to announce the formation of its formal scientific and business advisory board.
  • The seven-person advisory board assembles a wealth of experience and expertise with each member having a proven track record of excellence.
  • Dr. Alpert has taught for many years in entrepreneur programs at U.S. and overseas universities, mentoring students and faculty working in the healthcare industry.
  • Their collective knowledge and experience will be instrumental in guiding Pelvital as we embark on an exciting phase of growth and innovation."

Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry

Retrieved on: 
Tuesday, April 2, 2024
Kitchen, Bioreactor, Computational biology, IIA, Growth, Genetic distance, Generator, AI, Protein, TKH, Strauss Group, Pharming (genetics), USD, Food industry

REHOVOT, Israel, April 2, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments and The Kitchen FoodTech Hub (TKH), the foodtech incubator and investment arm of Israeli food giant Strauss Group, have jointly announced the establishment of Finally Foods Ltd.

Key Points: 
  • The company's mission is to modify plants as "bioreactors" to produce these proteins efficiently and environmentally responsibly.
  • Leveraging Evogene's GeneRator AI technology, the company aims for short R&D cycles and rapid time-to-market.
  • By harnessing the power of our GeneRator AI tech-engine, molecular farming has the potential to revolutionize the food industry and promote healthier diets worldwide."
  • "Establishing the company under the framework of The Kitchen and investing the pre-seed round was an easy decision in this case."

Evogene Announces Filing of Annual Report on Form 20-F

Retrieved on: 
Thursday, March 28, 2024
Contact, Annual, Computational biology, Annual report, Security (finance), Cryptocurrency

REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission.

Key Points: 
  • REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission.
  • The Annual Report on Form 20-F can be accessed on the Company's investor relations website https://evogene.com/investor-relations/ and on the SEC's website at http://www.sec.gov .
  • The Company's security holders may request a hard copy of the Annual Report free of charge by visiting the Contact Us page of the Company's website.